Chemotherapy for androgen-independent prostate cancer

Seminars in Urologic Oncology

Volumn 20, Issue 3 SUPPL. 1, 2002, Pages 31-35

  Petrylak, Daniel P ^a  

^a Columbia Presbyterian Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE;

AGED; ANEMIA; ANOREXIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; EDEMA; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; VASCULAR DISEASE;

EID: 0036671675     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.35052     Document Type: Article

References (26)

1. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
2. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
3. Cancer of the prostate
4. Cancer statistics 1999
5. Chemotherapy with mitoxantrone plus prednisone vs prednisone alone for symptomatic hormone refractory prostate cancer: A Canadian randomized trial with palliative endpoints
6. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
7. Overcoming bcl-2- and p53-mediated resistance in prostate cancer
8. Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention
9. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells
10. Chemotherapy for advanced hormone refractory prostate cancer
11. Bcl-2 is the guardian of microtubule integrity
12. Estramustine depolymerizes microtubules by binding to tubulin
13. Estramustine binds to a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU-145 cells
14. Estramustine phosphate sodium: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
15. Taxol in advanced hormone-refractory prostate carcinoma: A phase II trial of the Eastern Cooperative Oncology Group
16. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
17. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory, prostate cancer
18. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
19. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
20. Docetaxel (Taxotere) in hormone-refractory prostate cancer
21. A phase II study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer: CALGB 9780
22. A phase II study evaluating docetaxel (D) and one day estramustine (EMP) in patients (pts) with hormone refractory prostate cancer (HRPC)
23. A phase II study evaluating a one day course of estramustine phosphate (EMP) and docetaxel (D) in patients with hormone refractory prostate cancer
24. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (pts) with androgen-independent prostate cancer
25. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B Trial 9780
26. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B